This is a list of investigational hallucinogens and entactogens, or

hallucinogen Hallucinogens, also known as psychedelics, entheogens, or historically as psychotomimetics, are a large and diverse class of psychoactive drugs that can produce altered states of consciousness characterized by major alterations in thought, mo ...

s and

entactogen Entactogens, also known as empathogens or connectogens, are a class of psychoactive drugs that induce the production of experiences of emotional communion, oneness, connectedness, emotional openness—that is, empathy—as particularly observe ...

s that are currently under formal development for clinical use but are not yet approved. ''Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.'' The list also includes non-hallucinogenic drugs related to hallucinogens, such as non-hallucinogenic

serotonin Serotonin (), also known as 5-hydroxytryptamine (5-HT), is a monoamine neurotransmitter with a wide range of functions in both the central nervous system (CNS) and also peripheral tissues. It is involved in mood, cognition, reward, learning, ...

5-HT_2A receptor

agonist An agonist is a chemical that activates a Receptor (biochemistry), receptor to produce a biological response. Receptors are Cell (biology), cellular proteins whose activation causes the cell to modify what it is currently doing. In contrast, an R ...

s and non-hallucinogenic

ketamine Ketamine is a cyclohexanone-derived general anesthetic and NMDA receptor antagonist with analgesic and hallucinogenic properties, used medically for anesthesia, depression, and pain management. Ketamine exists as its S- (esketamine) a ...

analogues.

Cannabinoid Cannabinoids () are several structural classes of compounds found primarily in the ''Cannabis'' plant or as synthetic compounds. The most notable cannabinoid is the phytocannabinoid tetrahydrocannabinol (THC) (delta-9-THC), the primary psychoact ...

s, or

cannabinoid receptor Cannabinoid receptors, located throughout the body, are part of the endocannabinoid system of vertebrates a class of cell membrane receptors in the G protein-coupled receptor superfamily. As is typical of G protein-coupled receptors, the cann ...

modulators, are not included in this list. Many of the indications are not for continuous medication therapy but rather are for medication-assisted

psychotherapy Psychotherapy (also psychological therapy, talk therapy, or talking therapy) is the use of Psychology, psychological methods, particularly when based on regular Conversation, personal interaction, to help a person change behavior, increase hap ...

or short-term use only. The section that the drug is in corresponds to its highest developmental phase, not its phase for all listed indications. This list was last comprehensively updated in October 2024. It is likely to become outdated with time.

Under development

Preregistration

* Midomafetamine (MDMA; "ecstasy") – serotonin, norepinephrine, and dopamine releasing agent, weak serotonin 5-HT_2A, 5-HT_2B, 5-HT_2C receptor agonist, entactogen, and weak psychedelic hallucinogen – post-traumatic stress disorder, alcoholism, social anxiety in autism –

Multidisciplinary Association for Psychedelic Studies The Multidisciplinary Association for Psychedelic Studies (MAPS) is an American nonprofit organization working to raise awareness and understanding of psychedelic substances. MAPS was founded in 1986 by Rick Doblin and is now based in San Jose, C ...

(MAPS), Lykos Therapeutics

Phase 3

CYB003 CYB003, or CYB-003, also known as deuterated psilocybin analogue, is a serotonergic psychedelic related to psilocybin which is under development for the treatment of major depressive disorder, alcoholism, and other psychiatric disorders. It is t ...

(CYB-003; deuterated psilocybin analogue; deuterated psilocin; deupsilocin) – serotonin 5-HT_2A receptor agonist and psychedelic hallucinogen – major depressive disorder, alcoholism, psychiatric disorders –

Cybin Cybin IRL is a Canadian pharmaceutical company that is developing psychedelic drugs as medicines. The company's drug candidates include psilocybin (CYB001), CYB002 (discontinued), CYB003 ( deuterated psilocin), CYB004 (deuterated dimethyltrypta ...

Ketamine Ketamine is a cyclohexanone-derived general anesthetic and NMDA receptor antagonist with analgesic and hallucinogenic properties, used medically for anesthesia, depression, and pain management. Ketamine exists as its S- (esketamine) a ...

(AWKN-001, AWKN-P-001) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – alcoholism, binge-eating disorder, gambling, impulse control disorders, obsessive–compulsive disorder – Awakn Life Sciences *

(HTX-100; NRX-100) – ionotropic glutamate NMDA receptor antagonist – suicidal ideation, mental disorders – NRx Pharmaceuticals *

Lysergic acid diethylamide Lysergic acid diethylamide, commonly known as LSD (from German ; often referred to as acid or lucy), is a Semisynthesis, semisynthetic, Hallucinogen, hallucinogenic compound derived from ergot, known for its powerful psychological effects and ...

(LSD; lysergide; MM-120) – non-selective serotonin receptor agonist and psychedelic hallucinogen – anxiety disorders, attention-deficit hyperactivity disorder, cluster headache, major depressive disorder, pain – MindMed *

Psilocybin Psilocybin, also known as 4-phosphoryloxy-''N'',''N''-dimethyltryptamine (4-PO-DMT), is a natural product, naturally occurring tryptamine alkaloid and Investigational New Drug, investigational drug found in more than List of psilocybin mushroom ...

(COMP-360; COMP360) – non-selective serotonin receptor agonist and psychedelic hallucinogen – depressive disorders, anorexia nervosa, bipolar depression, major depressive disorder, post-traumatic stress disorder, somatoform disorders, pervasive child development disorders –

COMPASS Pathways Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin (COMP360), is currently in phase 3 clinical trials for treatment-resistant depression. ...

– non-selective serotonin receptor agonist and psychedelic hallucinogen – major depressive disorder, borderline personality disorder –

Usona Institute The Usona Institute is a 501(c)(3) non-profit medical research organization (MRO) which is developing psychedelic drugs for potential medical use. It was launched by scientist and entrepreneur Bill Linton, who is the founder of the biotechnology ...

Phase 2

Arketamine Arketamine (developmental code names PCN-101, HR-071603), also known as (''R'')-ketamine or (''R'')-(−)-ketamine, is the (''R'')-(−) enantiomer of ketamine. Similarly to racemic ketamine and esketamine, the ''S''(+) enantiomer of ke ...

((''R'')-ketamine; PCN-101) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – depressive disorders – ATAI Life Sciences * Blixeprodil (GM-1020; (''R'')-4-fluorodeschloroketamine; (''R'')-4-FDCK) – orally active NMDA receptor receptor antagonist – major depressive disorder, bipolar depression, depressive disorders – Gilgamesh Pharmaceuticals * Bretisilocin (GM-2505; 5F-MET; 5-fluoro-''N''-methyl-''N''-ethyltryptamine) – serotonin 5-HT_2A and 5-HT_2C receptor agonist, serotonin 5-HT_2B receptor antagonist, psychedelic hallucinogen, and serotonin releasing agent – major depressive disorder – Gilgamesh Pharmaceuticals *

CYB004 CYB004, or CYB-004, also known as deuterated dimethyltryptamine (dDMT), is a serotonergic psychedelic related to dimethyltryptamine (DMT) which is under development for the treatment of generalized anxiety disorder. It is administered by inhalat ...

(CYB-004; deuterated dimethyltryptamine; deuterated DMT; dDMT) – non-selective serotonin receptor agonist and psychedelic hallucinogen – generalized anxiety disorder – Cybin *

Dimethyltryptamine Dimethyltryptamine (DMT), also known as ''N'',''N''-dimethyltryptamine (''N'',''N''-DMT), is a Psychedelic drug, serotonergic hallucinogen and Investigational New Drug, investigational drug of the substituted tryptamine, tryptamine family tha ...

(DMT; BMND-01/BMND01, BMND-02/BMND02, BMND-03/BMND03) – non-selective serotonin receptor agonist and psychedelic hallucinogen – depressive disorders, fibromyalgia, substance-related disorders – Biomind Labs *

Esketamine Esketamine, sold under the brand names Spravato (for depression (mood), depression) and Ketanest (for anesthesia) among others, is the ''S''(+) enantiomer of ketamine. It is a dissociative hallucinogen drug used as a general anesthetic and as ...

(CLE-100) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – major depressive disorder, bipolar depression – Clexio Biosciences *

(Ereska; IN ketamine; ketamine IN; intranasal ketamine; intranasal racemic ketamine; PMI-100, PMI-150, SLS-002, TUR-002) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – post-traumatic stress disorder, suicidal ideation, acute pain, cancer pain – Seelos Therapeutics *

extended-release (R-107, R107) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – major depressive disorder – Douglas Pharmaceuticals *

prolonged-release

oral The word oral may refer to: Relating to the mouth * Relating to the mouth, the first portion of the alimentary canal that primarily receives food and liquid **Oral administration of medicines ** Oral examination (also known as an oral exam or ora ...

(KET-01) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – depressive disorders, neuropathic pain – Ketabon * Ketamine/temsirolimus (FREE001) – ionotropic glutamate NMDA receptor antagonist, dissociative hallucinogen, and mTOR inhibitor combination – major depressive disorder – Freedom Biosciences *

(LSD; lysergide; MB-22001/MB22001) – non-selective serotonin receptor agonist and psychedelic hallucinogen – major depressive disorder, existential distress in cancer patients – MindBio Therapeutics * Mebufotenin (5-MeO-DMT; BPL-002, BPL-003) – non-selective serotonin receptor agonist and psychedelic hallucinogen – alcoholism, major depressive disorder – Beckley Psytech * Mebufotenin (5-MeO-DMT; BMND-05/BMND05, BMND-08/BMND08) – non-selective serotonin receptor agonist and psychedelic hallucinogen – Alzheimer's disease, pain – Biomind Labs * Mebufotenin (5-MeO-DMT; GH001/GH-001; GH002/GH-002; GH003/GH-003) – non-selective serotonin receptor agonist and psychedelic hallucinogen – depressive disorders – GH Research *

Methylone Methylone, also known as 3,4-methylenedioxy-''N''-methylcathinone (MDMC), is an entactogen and stimulant drug of the amphetamine, cathinone, and benzodioxole families related to 3,4-methylenedioxymethamphetamine (MDMA; "ecstasy"). It is th ...

(MDMC; TSND-201) – serotonin, norepinephrine, and dopamine releasing agent and entactogen – post-traumatic stress disorders, major depressive disorder, CNS disorders – Transcend Therapeutics * Midomafetamine (MDMA; "ecstasy") – serotonin, norepinephrine, and dopamine releasing agent, weak serotonin 5-HT_2A, 5-HT_2B, 5-HT_2C receptor agonist, entactogen, and weak psychedelic hallucinogen – alcoholism – Awakn Life Sciences * Midomafetamine/citalopram (MDMA/citalopram) – serotonin, norepinephrine, and dopamine releasing agent, weak serotonin 5-HT_2A, 5-HT_2B, 5-HT_2C receptor agonist, entactogen, and weak psychedelic hallucinogen followed by a selective serotonin reuptake inhibitor – post-traumatic stress disorder – Tactogen * MSP-1014 (psilocin prodrug) – non-selective serotonin receptor agonist and psychedelic hallucinogen – major depressive disorder – Mindset Pharma, Otsuka America Pharmaceutical * Non-racemic midomafetamine (MDMA; "ecstasy"; 70–80% (''R'')-MDMA, 20–30% (''S'')-MDMA) – social anxiety in autism spectrum disorder – PharmAla Biotech * OSU-6162 (PNU-9639; PNU-96391; PNU-96391A) – non-hallucinogenic serotonin 5-HT_2A receptor partial agonist, dopamine D₂ receptor partial agonist, and sigma σ₁ receptor ligand (so-called "monoaminergic stabilizer") – bipolar depression, chronic fatigue syndrome, depressive disorders, stroke, subarachnoid hemorrhage, Parkinson's disease – Carlsson Research AB, Pfizer *

Psilocin Psilocin, also known as 4-hydroxy-''N'',''N''-dimethyltryptamine (4-HO-DMT), is a substituted tryptamine alkaloid and a serotonergic psychedelic. It is present in most psychedelic mushrooms together with its phosphorylated counterpart psilocy ...

– non-selective serotonin receptor agonist and psychedelic hallucinogen – adjustment disorder – Psyence BioMed *

– non-selective serotonin receptor agonist and psychedelic hallucinogen – generalized anxiety disorder – Diamond Therapeutics *

(low-dose; APEX-52 / 90) – non-selective serotonin receptor agonist and psychedelic hallucinogen – depressive disorders, anxiety disorders – Apex Laboratories *

– non-selective serotonin receptor agonist and psychedelic hallucinogen – Fragile X syndrome – restart Life Sciences *

(CYB-001; INT0052/2020) – non-selective serotonin receptor agonist and psychedelic hallucinogen – mental disorders, major depressive disorder, anxiety disorders – Cybin *

(MYCO-001, MYCO-003) – non-selective serotonin receptor agonist and psychedelic hallucinogen – post-traumatic stress disorder, anxiety disorders, depressive disorders, headache, substance-related disorders – Mydecine *

(PEX-010/PEX010) – non-selective serotonin receptor agonist and psychedelic hallucinogen – adjustment disorders, alcoholism, depressive disorders, anxiety disorders – Filament Health *

(PFN™; TRP-8802, TRP-8803, TRP-8804, TRYP-0082) – non-selective serotonin receptor agonist and psychedelic hallucinogen – binge-eating disorder, fibromyalgia, irritable bowel syndrome, cancer, complex regional pain syndrome, pain – Tryp Therapeutics *

(Psi-GAD; PSX-001) – non-selective serotonin receptor agonist and psychedelic hallucinogen – generalized anxiety disorder – Incannex *

(RSTP-1000) – non-selective serotonin receptor agonist and psychedelic hallucinogen – demoralization syndrome – Reset Pharma *

(SYNP-101; synthetic psilocybin) – alcoholism, obsessive–compulsive disorders, cluster headache, migraine – Ceruvia Lifesciences * RE-104 (RE104; FT-104/FT104; 4-HO-DiPT/iprocin prodrug) – serotonin 5-HT_2A receptor agonist and psychedelic hallucinogen – postnatal depression – Reunion Neuroscience *

Xenon Xenon is a chemical element; it has symbol Xe and atomic number 54. It is a dense, colorless, odorless noble gas found in Earth's atmosphere in trace amounts. Although generally unreactive, it can undergo a few chemical reactions such as the ...

(NBTX-001) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – post-traumatic stress disorder, Alzheimer's disease, irritable bowel syndrome, Parkinson's disease, pervasive child development disorders, panic disorder – Nobilis Therapeutics * Zolunicant (18-methoxycoronaridine; 18-MC; MM-110) – α₃β₄ nicotinic acetylcholine receptor antagonist, other actions – leishmaniasis, opioid-related disorders, substance-related disorders – MindMed

Phase 1/2

(DMT; SPL-026) – non-selective serotonin receptor agonist and psychedelic hallucinogen – major depressive disorder – Small Pharma, Cybin * Dimethyltryptamine/harmine (DMT/harmine; RE01) – non-selective serotonin receptor agonist, psychedelic hallucinogen, and monoamine oxidase inhibitor combination – generalized anxiety disorder – reconnect Labs *

Ibogaine Ibogaine is a psychoactive indole alkaloid derived from plants such as '' Tabernanthe iboga'', characterized by hallucinogenic and oneirogenic effects. Traditionally used by Central African foragers, it has undergone controversial research ...

(IBX-210) – various actions and hallucinogen – opioid-related disorders – ATAI Life Sciences/DemeRx * Mebufotenin (5-MeO-DMT; RE02) – non-selective serotonin receptor agonist and psychedelic hallucinogen – generalized anxiety disorder – reconnect Labs *

(PSY-0.1, PSY-0.2, PSY-0.3, PSY-0.4/0.5, PSY-0.6) – non-selective serotonin receptor agonist and psychedelic hallucinogen – substance-related disorders, neurological disorders, opioid-related disorders, psychiatric disorders, traumatic brain injury, cancer, anxiety disorders, bipolar disorders, depressive disorders, eating disorders, and additional unspecified conditions – Revive Therapeutics *

infusion Infusion is the process of extracting chemical compounds or flavors from plant material in a solvent such as water, oil or alcohol, by allowing the material to remain suspended in the solvent over time (a process often called steeping). An inf ...

(ELE-101, ELE-Psilo, ELE-Psilo+) – non-selective serotonin receptor agonist and psychedelic hallucinogen – major depressive disorder –

Eleusis Elefsina () or Eleusis ( ; ) is a suburban city and Communities and Municipalities of Greece, municipality in Athens metropolitan area. It belongs to West Attica regional unit of Greece. It is located in the Thriasio Plain, at the northernmost ...

, Beckley Psytech

Phase 1

* 2-Bromo-LSD (bromolysergide; BOL-148; NYPRG-101) – non-hallucinogenic serotonin 5-HT_2A receptor agonist and other actions – cluster headache, migraine – Ceruvia Lifesciences * 5-Methoxy-2-aminoindane (5-MeO-AI; MEAI; CMND-100) – serotonin releasing agent and entactogen – alcoholism, cocaine use disorder, metabolic syndrome, obesity – Clearmind Medicine * 5-MeO-MiPT (MSD-001; "moxy") – non-selective serotonin receptor agonist and psychedelic hallucinogen – undefined indication – Mindstate Design Labs * (''R'')-Midomafetamine ((''R'')-MDMA; (''R'')-methylenedioxymetamfetamine; MM-402) – serotonin, norepinephrine, and dopamine releasing agent, weak serotonin 5-HT_2A, 5-HT_2B, 5-HT_2C receptor agonist, entactogen, and weak psychedelic hallucinogen – pervasive child development disorders/autism spectrum disorder – MindMed * (''R'')-Midomafetamine ((''R'')-MDMA; ''R''-MDMA; EMP-01) – serotonin, norepinephrine, and dopamine releasing agent, weak serotonin 5-HT_2A, 5-HT_2B, 5-HT_2C receptor agonist, entactogen, and weak psychedelic hallucinogen – post-traumatic stress disorder, social phobia – EmpathBio * BMND07 (BMND-07; dimethyltryptamine or 5-MeO-DMT combination drug) – non-selective serotonin receptor agonist, serotonergic hallucinogen, and other actions combination – major depressive disorder – Biomind Labs *

(DMT; AP-188; IV DMT) – non-selective serotonin receptor agonist and psychedelic hallucinogen – stroke – Algernon Neuroscience *

(DMT; EBRX-101) – non-selective serotonin receptor agonist and psychedelic hallucinogen – smoking withdrawal, alcoholism – Entheon Biomedical *

(DMT; VLS-01; buccal DMT film) – non-selective serotonin receptor agonist and psychedelic hallucinogen – depressive disorders – ATAI Life Sciences, Viridia Life Sciences * Dimethyltryptamine/β-carboline (DMT/β-carboline) – non-selective serotonin receptor agonist, psychedelic hallucinogen, and monoamine oxidase inhibitor combination – undisclosed – Psychae Therapeutics *

((''S'')-ketamine; ''S''-ketamine; AWKN-002) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – alcoholism – Awakn Life Sciences *

(Keticap) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – mood disorders – Neurocentrx Pharma *

Ketanserin Ketanserin, sold under the brand name Sufrexal, is an antihypertensive agent which is used to treat arterial hypertension and vasospasm, vasospastic disorders. It is also used in scientific research as an antiserotonergic medication, agent in th ...

– serotonin 5-HT_2A and α₁-adrenergic receptor antagonist – hallucinogen antidote – MindMed *

Lys-MDA Lys-MDA (Lysine-MDA, N-(L-lysinamidyl)-3,4-methylenedioxyamphetamine) is a substituted amphetamine derivative with empathogenic effects, which acts as a prodrug for Methylenedioxyamphetamine, MDA with a slower onset of effects and longer duration ...

– methylenedioxyamphetamine (MDA) prodrug (serotonin, norepinephrine, and dopamine releasing agent, weak serotonin 5-HT_2A, 5-HT_2B, and 5-HT_2C receptor agonist, entactogen, and weak psychedelic hallucinogen) – unknown – MindMed, MiHKAL *

Lys-MDMA Lys-MDMA, or lysine-MDMA, also known as ''N''-(L-lysinamidyl)-MDMA, is a prodrug of MDMA which is being investigated for possible use as a pharmaceutical drug in the treatment of psychiatric disorders. Structurally, lys-MDMA is to MDMA as lisdexa ...

– midomafetamine (MDMA) prodrug (serotonin, norepinephrine, and dopamine releasing agent, weak serotonin 5-HT_2A, 5-HT_2B, and 5-HT_2C receptor agonist, entactogen, and weak psychedelic hallucinogen) – unknown – MindMed, MiHKAL * Mebufotenin (5-MeO-DMT) – non-selective serotonin receptor agonist and psychedelic hallucinogen – undisclosed – Usona Institute * Mebufotenin (5-MeO-DMT) – non-selective serotonin receptor agonist and psychedelic hallucinogen – substance use disorders – Alvarius Pharmaceuticals *

Mescaline Mescaline, also known as mescalin or mezcalin, and in chemical terms 3,4,5-trimethoxyphenethylamine, is a natural product, naturally occurring psychedelic drug, psychedelic alkaloid, protoalkaloid of the substituted phenethylamine class, found ...

(BMND-06/BMND06, BMND-09/BMND09) – non-selective serotonin 5-HT_2A receptor agonist and psychedelic hallucinogen – obesity, Parkinson's disease, inflammation – Biomind Labs *

(JOUR-5700) – non-selective serotonin receptor agonist and psychedelic hallucinogen – alcoholism – Journey Colab *

Noribogaine Noribogaine (actually ''O''-desmethylibogaine), or 12-hydroxyibogamine, is the principal psychoactive metabolite of the oneirogen ibogaine. It is thought to be involved in the antiaddictive effects of ibogaine-containing plant extracts, such as ...

(DMX-1001) – various actions – alcohol use disorder – DemeRx *

(MLS-101/MLS101) – non-selective serotonin receptor agonist and psychedelic hallucinogen – neuropsychiatric disorders, opioid use disorder, obsessive–compulsive disorder, premenstrual dysphoric disorder – MycoMedia Life Sciences *

(REL-P11) – non-selective serotonin receptor agonist and psychedelic hallucinogen – neurodegenerative disorders, metabolic disorders, psychiatric disorders – Arbormentis, Relmada Therapeutics * Zalsupindole (DLX-001; DLX-1; AAZ; AAZ-A-154) – non-hallucinogenic serotonin 5-HT_2A receptor agonist – CNS disorders, major depressive disorder – Delix Therapeutics

Preclinical

* 2-Bromo-LSD (bromolysergide; BOL-148; BETR-001, TD-0148A) – non-hallucinogenic serotonin 5-HT_2A receptor agonist and other actions – cluster headache, major depressive disorder, neuropathic pain, post-traumatic stress disorders – Transcend Biodynamics, BetterLife Pharma * 2-Fluorodeschloroketamine (2-FDCK) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – major depressive disorder – Clearmind Medicine *

3-Methylmethcathinone 3-Methylmethcathinone (3-MMC), also known as metaphedrone, is a designer drug from the substituted cathinone family. 3-MMC is a monoamine transporter substrate (a substance acted upon by monoamine transporters in the brain) that potently releas ...

(3-MMC; metaphedrone) – serotonin, norepinephrine, and dopamine releasing agent and entactogen – dyskinesias – Clearmind Medicine * AKO-001 (dimethyltryptamine/specific plant bioactive; DMT/specific plant bioactive) – non-selective serotonin receptor agonist, psychedelic hallucinogen, and "specific plant bioactive" combination – stroke – Akome Biotech * AKO-002 (psilocybin-based formulation; psilocybin/specific plant bioactive) – non-selective serotonin receptor agonist, psychedelic hallucinogen, and "specific plant bioactive" combination – Alzheimer's disease – Akome Biotech * AKO-003 (ketamine-based psychedelic formulation; ketamine/specific plant bioactive) – ionotropic glutamate NMDA receptor antagonist, dissociative hallucinogen, and "specific plant bioactive" combination – major depressive disorder – Akome Biotech * AKO-004 (dimethyltryptamine/specific plant bioactive; DMT/specific plant bioactive) – non-selective serotonin receptor agonist, psychedelic hallucinogen, and "specific plant bioactive" combination – Parkinson's disease – Akome Biotech * BMB-201 (BMB-A39a prodrug) – non-hallucinogenic serotonin 5-HT_2A and 5-HT_2C receptor agonist and psychoplastogen – generalized anxiety disorder, pain – Bright Minds Biosciences https://brightmindsbio.com/wp-content/uploads/2024/09/BMB_investor_deck_September.pdf * BMB-202 – selective serotonin 5-HT_2A receptor agonist and psychedelic hallucinogen – depressive disorders, post-traumatic stress disorder – Bright Minds Biosciences * CT-4201 (psilocin prodrug) – non-selective serotonin receptor agonist and psychedelic hallucinogen – major depressive disorder – CaaMTech *

(DMT) – non-selective serotonin receptor agonist and psychedelic hallucinogen – psychiatric disorders, social phobia – Psilera * DLX-159 (tryptamine derivative) – undisclosed mechanism of action, serotonin 5-HT_2B receptor antagonist, and psychoplastogen – major depressive disorder, psychiatric disorders – Delix Therapeutics * EB-002 (EB-373; psilocin prodrug) – non-selective serotonin receptor agonist and psychedelic hallucinogen – anxiety disorders – Enveric Biosciences * EB-003 – non-hallucinogenic serotonin receptor agonist and psychoplastogen – anxiety disorders, depressive disorders – Enveric Biosciences * EGX-A – serotonin 5-HT_2A receptor agonist and psychedelic hallucinogen – depressive disorders – ATAI Life Sciences, Entheogenix Biosciences https://ir.atai.life/static-files/d589b5ff-b604-4321-925e-3f01fb7f7911 * EGX-B – serotonin 5-HT_2A receptor agonist and psychedelic hallucinogen – depressive disorders – ATAI Life Sciences, Entheogenix Biosciences * EGX-121 – undefined mechanism of action (non-tryptamine new chemical entity) – undisclosed – atai Life Sciences * ENX-105 – dopamine D₂ and D₃ receptor antagonist and non-hallucinogenic serotonin 5-HT_1A and 5-HT_2A receptor agonist – mood disorders, post-traumatic stress disorder – Engrail Therapeutics * EQL-101 – undefined mechanism of action (non-hallucinogenic non-cardiotoxic ibogaine derivative) – substance use disorders – Equulus Therapeutics * GM-3009 (ibogaine analogue(s); GMX-3009) – various actions – opioid-related disorders, post-traumatic stress disorder, traumatic brain injury – Gilgamesh Pharmaceuticals * GM-5022 – undefined mechanism of action (non-hallucinogenic psychoplastogen) – depressive disorders, anxiety disorders, neurological disorders – Gilgamesh Pharmaceuticals * HBL20017 – non-hallucinogenic non-selective serotonin receptor agonist – obsessive–compulsive disorder – Negev Labs, Parow Entheobiosciences *

– various actions and hallucinogen – CNS disorders, neuropathic pain, traumatic brain injury – MINDCURE * Ibogaine derivatives - Terran Biosciences – various actions and potential hallucinogens – neurological disorders, psychiatric disorders – Terran Biosciences * ITI-1549 – non-hallucinogenic serotonin 5-HT_2A receptor agonist, serotonin 5-HT_2B receptor antagonist, and psychoplastogen – psychiatric disorders – Intra-Cellular Therapies *

depot (ALA-3000) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – depressive disorders – Alar Pharmaceuticals *

subcutaneous (BB-106/BB106 ) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – acute pain, mental disorders – Bexson Biomedical * Ketamine analogue (Ketamir, Ketamir-2) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – depressive disorders – MIRA Pharmaceuticals * Long-acting MDMA prodrug (long-acting midomafetamine prodrug) – serotonin, norepinephrine, and dopamine releasing agent, weak serotonin 5-HT_2A, 5-HT_2B, and 5-HT_2C receptor agonist, entactogen, and weak psychedelic hallucinogen – neurological disorders, psychiatric disorders – Terran Biosciences * LPH-5 (novel phenethylamine) – selective serotonin 5-HT_2A receptor partial agonist and psychedelic hallucinogen – major depressive disorder – Lophora, Beckley Psytech * LPH-48 (shorter-acting LPH-5 analogue) – undefined mechanism of action and serotonergic hallucinogen – alcoholism – Lophora * Lucid-PSYCH (Lucid-201) – undefined mechanism of action and psychedelic hallucinogen – major depressive disorder – Lucid Psycheceuticals *

(LSD; lysergide) – non-selective serotonin receptor agonist and psychedelic hallucinogen – neurological disorders, psychiatric disorders – Delix Therapeutics * MBDB – serotonin and norepinephrine releasing agent, weak serotonin 5-HT₁ and 5-HT₂ receptor ligand, and entactogen – autism – PharmAla Biotech * Mebufotenin (5-MeO-DMT; LSR-1019) – non-selective serotonin receptor agonist and psychedelic hallucinogen – depressive disorders, psychiatric disorders – Lusaris Therapeutics * Midomafetamine microneedle

transdermal patch A transdermal patch is a medicated adhesive patch that is placed on the skin to deliver a specific Dose (biochemistry), dose of medication through the skin and into the bloodstream. An advantage of a transdermal drug delivery route over ot ...

(MDMA; "ecstasy") – serotonin, norepinephrine, and dopamine releasing agent, weak serotonin 5-HT_2A, 5-HT_2B, and 5-HT_2C receptor agonist, entactogen, and weak psychedelic hallucinogen – anxiety disorders, depressive disorders, post-traumatic stress disorder, substance-related disorders – PharmaTher, Revive Therapeutics * MSP-4018 – serotonin 5-HT_1A and 5-HT_2A receptor agonist and psychedelic hallucinogen (5-MeO-DMT- and DMT-inspired drug) – neurological disorders, psychiatric disorders – Mindset Pharma, Otsuka America Pharmaceutical * MSP-4019 – undefined mechanism of action (5-MeO-DMT- and DMT-inspired drug) – neurological disorders, psychiatric disorders – Mindset Pharma, Otsuka America Pharmaceutical * MSP-4020 – undefined mechanism of action (5-MeO-DMT- and DMT-inspired drug) – neurological disorders, psychiatric disorders – Mindset Pharma, Otsuka America Pharmaceutical * MYCO-006 – undefined mechanism of action and short-acting MDMA-like entactogen – anxiety disorders – Mydecine * MYCO-007 – undefined mechanism of action and short-acting MDMA-like entactogen – undefined indication – Mydecine * Non-racemic midomafetamine (non-racemic MDMA; AM-1002) – undefined mechanism of action (non-neurotoxic, non-racemic form of MDMA) – post-traumatic stress disorder – Arcadia Medicine https://arcadiamedicine.com/ * Norbaeocystin – non-hallucinogenic serotonin 5-HT_2A receptor agonist and other actions – mental disorders – PsyBio Therapeutics * PSIL-001 (DMT analogue) – non-hallucinogenic serotonin 5-HT₁ receptor modulator – depressive disorders, mood disorders, neurodegenerative disorders, substance-related disorders – Psilera * PSIL-002 (DMT analogue) – non-hallucinogenic serotonin 5-HT₁ receptor modulator – depressive disorders, mood disorders, neurodegenerative disorders, substance-related disorders – Psilera * PSIL-006 – non-hallucinogenic serotonin 5-HT_2A and 5-HT₆ receptor partial agonist – frontotemporal dementia – Psilera * PSIL-020 – non-hallucinogenic serotonin 5-HT₆ receptor agonist – undisclosed – Psilera * PSIL-025 – non-hallucinogenic serotonin 5-HT₁ receptor modulator – anxiety disorders – Psilera * Psilacetin (''O''-acetylpsilocin; 4-AcO-DMT) – non-selective serotonin receptor agonist and psychedelic hallucinogen – substance-related disorders – Psilera *

(PLZ-1015) – non-selective serotonin receptor agonist and psychedelic hallucinogen – pervasive child development disorders – Pilz Bioscience * RE-245 – non-hallucinogenic serotonin receptor agonist and psychoplastogen – undisclosed – Reunion Neuroscience * Research programme: hydroxynorketamine derivatives - Spirify Pharma – amino acid modulators and serine protease modulators – depressive disorders, pain – Spirify Pharma * Research programme: Ibogaine analogues - Gilgamesh Pharmaceuticals (GM-300X) – various actions – opioid-related disorders – Gilgamesh Pharmaceuticals * Research programme: mental disorder therapeutics - Cybin (Deuterated DMT series - Cybin) – serotonin receptor modulators and psychedelic hallucinogens – mental disorders – Small Pharma, Cybin * Research programme: micro-dose serotonergics - Gilgamesh Pharmaceuticals – serotonin receptor agonists – attention-deficit hyperactivity disorder, major depressive disorder – Gilgamesh Pharmaceuticals * Research programme: non-hallucinogenic psychedelic therapeutics - Intra-Cellular Therapies (ITI-1500) – undefined mechanism of action – psychiatric disorders – Intra-Cellular Therapies * Research programme: psilocin derivatives - Enveric Biosciences – serotonin 5-HT_2A receptor agonists and potential psychedelic hallucinogens – mental disorders – Enveric Biosciences * Research programme: psilocin prodrugs and derivatives - Terran Biosciences – serotonin 5-HT_2A receptor agonists and psychedelic hallucinogens – neurological disorders, psychiatric disorders – Terran Biosciences * Research programme: psychedelic and empathogenic compounds - Terran Biosciences – serotonin receptor modulators – neurological disorders, psychiatric disorders – Terran Biosciences * Research programme: psychedelic-based neurological therapeutics - Psilera – undefined mechanism and psychedelic hallucinogens – alcoholism, anxiety disorders, depressive disorders, neurodegenerative disorders – Psilera * Research programme: psychedelic-based therapeutics - Clearmind Medicine/SciSparc – undefined mechanism of action – metabolic disorders, obesity, psychiatric disorders – Clearmind Medicine, SciSparc * Research programme: psychedelic microneedle patch - PharmaTher – undefined mechanism of action – neurological disorders, neuromuscular disorders, pain, psychiatric disorders – PharmaTher * Research programme: psychoplastogen therapeutics - Collaborations Pharmaceuticals – undefined mechanism of action – opioid-related disorders – Collaborations Pharmaceuticals * Research programme: serotonin 2A receptor agonists - Bright Minds Biosciences – serotonin 5-HT_2A receptor agonists – major depressive disorder, post-traumatic stress disorder – Bright Minds Biosciences * Research programme: serotonin 2A/C receptor agonists - Bright Minds Biosciences – serotonin 5-HT_2A and 5-HT_2C receptor agonists – pain – Bright Minds Biosciences * Research programme: small tryptamine derivatives - Marvel Biosciences (non-hallucinogenic neuroplasticity program - Marvel Biosciences) – adenosine A_2A receptor antagonists – depressive disorders – Marvel Biosciences * Research programme: SPL 029 series - Cybin (Oral DMT series - Cybin; SPL029) – non-selective serotonin receptor agonist and psychedelic hallucinogen – mental disorders – Small Pharma, Cybin * SENS-01 – undefined mechanism of action ("highly selective fast-acting anxiolytic without sedation") – social anxiety disorder, anxiety disorders, depressive disorders – Sensorium Therapeutics * Serotonin 5-HT2 receptor agonists - Cybin – serotonin 5-HT₂ receptor agonists (phenethylamines) – neurological disorders, psychiatric disorders – Cybin * Tabernanthalog (TBG; DLX-007; DLX-7) – non-hallucinogenic serotonin 5-HT_2A receptor agonist – CNS disorders – Delix Therapeutics * TACT411 – serotonin 5-HT_1B receptor modulator and monoamine transporter modulator – alcohol use disorder, anorexia, binge-eating disorder – Tactogen * TACT523 – undefined mechanism of action – alcohol use disorder, anorexia, binge-eating disorder – Tactogen * TACT833 – serotonin 5-HT_1B receptor modulator and monoamine transporter modulator – alcohol use disorder, anorexia, binge-eating disorder – Tactogen * TACT908 – serotonin 5-HT_1B receptor agonist and non-hallucinogenic serotonin 5-HT_2A receptor partial agonist – cluster headache – Tactogen * TN-001 – non-hallucinogenic serotonin 5-HT_2A receptor partial agonist and serotonin 5-HT_2B receptor antagonist and neuroplastogen – major depressive disorder, post-traumatic stress disorder – Transneural Therapeutics, CaaMTech * Triptax – undefined mechanism of action – depressive disorders – Biomind Labs * XYL-1001 (PSYLO-1001; PSYLO-100X) – non-hallucinogenic serotonin 5-HT_2A and 5-HT₆ receptor modulator and psychoplastogen – mental disorders – Psylo/Xylo * XYL-1002 (PSYLO-1002; Psylo-1002) – non-hallucinogenic serotonin 5-HT_2A receptor agonist, other actions, and psychoplastogen – anxiety disorders – Psylo * XYL-3001 (XYL-300X; PSYLO-3001; Psylo-3001) – non-hallucinogenic non-selective serotonin receptor agonist and psychoplastogen – depressive disorders, generalized anxiety disorder, social phobia – Psylo * XYL-4001 (XYL-400X; PSYLO-4001; Psylo-4001) – non-hallucinogenic serotonin 5-HT_2A receptor agonist and psychoplastogen – depressive disorders, major depressive disorder – Psylo

Research

* AM-1004 – undefined mechanism of action (short-acting psychoactive/entactogen combination) – major depressive disorder – Arcadia Medicine * AM-1006 – undefined mechanism of action (short-acting subperceptual psychoactive drug) – substance use disorders – Arcadia Medicine *

ASR-2001 ASR-2001, also known as 2CB-5PrO or as 4-bromo-2-methoxy-5-propoxyphenethylamine, is a non-hallucinogenic serotonin receptor agonist of the phenethylamine, 2C, and TWEETIO families which is under development for the treatment of psychiatric dis ...

(2CB-5PrO) – non-hallucinogenic serotonin 5-HT_2A and 5-HT_1B receptor agonist – psychiatric disorders – Alexander Shulgin Research Institute * ASR-3001 (5-MeO-iPALT) – non-selective serotonin receptor agonist and psychedelic hallucinogen – psychiatric disorders – Alexander Shulgin Research Institute * Baeocystin (PLZ-1019) – non-hallucinogenic serotonin 5-HT_2A receptor agonist and other actions – pervasive developmental disorders in children – Pilz Bioscience *

Bufotenin Bufotenin, also known as dimethylserotonin or as 5-hydroxy-''N'',''N''-dimethyltryptamine (5-HO-DMT), is a serotonergic psychedelic of the tryptamine family. It is a derivative of the psychedelic dimethyltryptamine (DMT) and of the neurotransmi ...

(bufotenine) – non-selective serotonin receptor agonist and psychedelic hallucinogen – undisclosed – Usona Institute *

CYB005 CYB005, or CYB-005, also known as deuterated phenethylamine derivative, is a serotonin receptor agonist and serotonergic psychedelic which is under development for use at non-hallucinogenic doses in the treatment of psychiatric disorders and neur ...

(CYB-005; deuterated phenethylamine derivative) – undefined mechanism of action ("non-hallucinogenic doses") – psychiatric disorders – Cybin *

– various actions – anorexia nervosa, neurological disorders, substance-related disorders – Biomind Labs * LSR-3000 – undefined mechanism of action (tryptamine serotonergic neuroplastogen) – neurological disorders – Lusaris Therapeutics *

(LSD; lysergide; LSD-CUREfilm) – non-selective serotonin receptor agonist and psychedelic hallucinogen – mental disorders – CURE Pharmaceutical * Mebufotenin (5-MeO-DMT; LSR-2000) – non-selective serotonin receptor agonist and psychedelic hallucinogen – alcoholism, major depressive disorder – Lusaris Therapeutics *

(BMND-04/BMND04) – non-selective serotonin receptor agonist and psychedelic hallucinogen – eating disorders, neurological disorders – Biomind Labs * Midomafetamine (MDMA; "ecstasy"; MDMA-CUREfilm) – serotonin, norepinephrine, and dopamine releasing agent, weak serotonin 5-HT_2A, 5-HT_2B, and 5-HT_2C receptor agonist, entactogen, and weak psychedelic hallucinogen – mental disorders – CURE Pharmaceutical * MYCO-002 – undefined mechanism of action and MDMA-like entactogen – mental disorders – Mydecine * MYCO-004 (patch-delivered tryptamine compound) – undefined mechanism of action and psychedelic hallucinogen – smoking withdrawal, substance-related disorders – Mydecine * MYCO-005 (psilocin analogue) – serotonin 5-HT_2A receptor agonist and psychedelic hallucinogen – anxiety disorders, depressive disorders – Mydecine * ''N''-Methyltryptamine (NMT; monomethyltryptamine) – undefined mechanism of action and psychedelic hallucinogen – unspecified – Core One Labs * Noribogaine derived therapeutic – various actions – opioid-related disorders – Mindmed, Nextage Therapeutics * Norpsilocin (PLZ-1017) – non-hallucinogenic serotonin 5-HT_2A receptor agonist and other actions – pervasive developmental disorders in children – Pilz Bioscience *

– non-selective serotonin receptor agonist and psychedelic hallucinogen – cancer – Dominari Holdings * PSYLO-5001 (Psylo-5001) – non-hallucinogenic serotonin 5-HT_2A receptor agonist and psychoplastogen – mental disorders – Psylo * Research programme: 3,4-Methylenedioxymetamfetamine derivatives - Enveric Biosciences – serotonin, norepinephrine, and/or dopamine releasing agents and entactogens – mental disorders, neurological disorders, psychotic disorders – MagicMed Industries, Enveric Biosciences * Research programme: Ibogaine derivatives - MindMed/Nextage Therapeutics – various actions and potential hallucinogens – opioid-related disorders – Mindmed, Nextage Therapeutics * Research programme: lysergic acid diethylamide derivatives - Enveric Biosciences – serotonin 5-HT_2A receptor agonists – mental disorders, neurological disorders, psychotic disorders – MagicMed Industries, Enveric Biosciences * Research programme: mescaline derivatives - Enveric Biosciences – serotonin 5-HT₂ receptor agonists – mental disorders, neurological disorders – MagicMed Industries, Enveric Biosciences * Research programme: non-hallucinogenic psychedelic therapeutics - Sintalica Bioscience/University of Messina – undefined mechanism of action and non-hallucinogenic tryptamine serotonergic agents – Sintalica Bioscience, University of Messina * Research programme: psychiatric disorder therapies (neuroplastogens) - AbbVie/Gilgamesh Pharmaceuticals – undefined mechanism of action – psychiatric disorders – AbbVie, Gilgamesh Pharmaceuticals * Research programme: non-hallucinogenic psychiatric therapies - Daiichi Sankyo/Psylo – undefined mechanism of action – mental disorders – Daiichi Sankyo, Psylo * Research programme: non-tryptamine psychedelic small molecules - Otsuka America Pharmaceutical – serotonin receptor modulators – neurological disorders, psychiatric disorders – Mindset Pharma, Otsuka America Pharmaceutical * Research programme: psychedelic and empathogenic therapeutics - COMPASS Pathways – undefined mechanism of action – mental disorders – COMPASS Pathways, MiHKAL * Research programme: psychedelic and empathogenic compounds subcutaneous - Bexson Biomedical – undefined mechanism of action – depressive disorders, mental disorders, pain, post-traumatic stress disorder, substance-related disorders – Bexson Biomedical * Research programme: psychedelic therapeutics - COMPASS Discovery Center – serotonin 5-HT_2A receptor modulators – mental disorders – COMPASS Discovery Center, COMPASS Pathways * Research programme: tryptamine analog therapeutics - Diamond Therapeutics – serotonin receptor modulators – Diamond Therapeutics * SPT-348 – serotonin receptor modulator and non-hallucinogenic psychoplastogen (prodrug of 2-bromo-LSD) – mood disorders, depression and anxiety, neuropsychiatric disorders – Seaport Therapeutics

Not under development

Development suspended

((''S'')-ketamine; AM-101; esketamine otic gel; Keyzilen) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – tinnitus – Altamira Therapeutics

No development reported

2C-iBu 2,5-Dimethoxy-4-isobutylphenethylamine (2C-iBu or 2C-IB), also known by its developmental code name ELE-02, is a serotonin 5-HT2A receptor agonist, serotonergic psychedelic, and anti-inflammatory drug which is under development for the treatmen ...

(ELE-02) – serotonin 5-HT_2A receptor agonist, psychedelic hallucinogen, and anti-inflammatory agent – inflammation – Eleusis *

((''R'')-ketamine; HR-071603; (''R'')-ketamine nasal spray) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – depressive disorders – Jiangsu Hengrui Medicine *

((''S'')-ketamine; esketamine DPI; Falkieri; PG061) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – bipolar depression, depressive disorders – Celon Pharma *

((''S'')-ketamine; IPX-237, IPX237-C0001, IPX237-C0002, IPX237-L0001) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – unspecified – IMPAX Laboratories, Amneal Laboratories *

Hydroxynorketamine Hydroxynorketamine (HNK), or 6-hydroxynorketamine, is a minor metabolite of the anesthetic, dissociative, and antidepressant drug ketamine. It is formed by hydroxylation of the intermediate norketamine, another metabolite of ketamine. As of lat ...

((2''R'',6''R'')-hydroxynorketamine; 6-HNK; SPL-801-B) – unknown mechanism of action (non-hallucinogenic ketamine derivative and metabolite) – depressive disorders – Small Pharma, Cybin *

(ELE-Ket+) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – major depressive disorder – Beckley Psytech *

intranasal Nasal administration, popularly known as snorting, is a route of administration in which drugs are insufflation (medicine), insufflated through the nose. It can be a form of either topical administration or systemic administration, as the drugs t ...

– ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – cluster headaches – CCH Pharmaceuticals *

intravenous Intravenous therapy (abbreviated as IV therapy) is a medical technique that administers fluids, medications and nutrients directly into a person's vein. The intravenous route of administration is commonly used for rehydration or to provide nutr ...

(Braxia) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – depressive disorders – Braxia Scientific *

sublingual Sublingual (List of abbreviations used in medical prescriptions, abbreviated SL), from the Latin for "under the tongue", refers to the pharmacological route of administration by which substances diffuse into the blood through Tissue (biology), t ...

(ketamine wafer; SLS-003; Wafermine) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – acute pain, dental pain, pain, depressive disorders – iX Biopharma *

(SHX-001) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – major depressive disorder – Shenox Pharmaceuticals * Midomafetamine (MDMA; "ecstasy") – serotonin, norepinephrine, and dopamine releasing agent, weak serotonin 5-HT_2A, 5-HT_2B, and 5-HT_2C receptor agonist, entactogen, and weak psychedelic hallucinogen – mood disorders, substance-related disorders – MindMed *

(biosynthetic psilocybin; PB-1818) – non-selective serotonin receptor agonist and psychedelic hallucinogen – depressive disorders – PsyBio Therapeutics *

(low-dose psilocybin; BPL-PSILO) – non-selective serotonin receptor agonist and psychedelic hallucinogen – headache – Beckley Psytech * Research programme: ketamine derivatives - Shenox Pharmaceuticals (SHX-004; SHX-004/005/006/007/011; SHX-005; SHX-006; SHX-007; SHX-011) – ionotropic glutamate NMDA receptor antagonists and dissociative hallucinogens – major depressive disorder, neuropathic pain – Shenox Pharmaceuticals * Research programme: serotonin psychedelics - Mydecine Innovations Group – serotonin modulators and psychedelic hallucinogens – mental disorders – Mydecine * Research programme: tryptamine based therapeutics - PsyBio Therapeutics – serotonin 5-HT_2A receptor agonists – anxiety disorders, depressive disorders, post-traumatic stress disorder, substance-related disorders – PsyBio Therapeutics * XW-10508 (oral esketamine conjugate prodrug) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – major depressive disorder, pain – XWPharma

Development discontinued

(Ketals) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – amyotrophic lateral sclerosis, anaesthesia, drug-induced dyskinesia, Rett syndrome – PharmaTher *

– ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – autistic disorder – Roivant Sciences * Research programme: ketamine deuterated - Teva Pharmaceutical Industries – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – pain – Teva Pharmaceutical Industries *

Salvinorin A Salvinorin A is the main active psychotropic molecule in '' Salvia divinorum''. Salvinorin A is considered an atypical dissociative hallucinogen. It is structurally distinct from other naturally occurring hallucinogens (such as DMT, psil ...

(INT0054/2020; RLS-01) – κ-opioid receptor agonist – depressive disorders, unspecified – Revixia Life Sciences IntelGenx Corp

20th century (1940s–1980s)

* 3-(2-Aminopropyl)benzo(β)thiophene (3-APBT; SKF-6678) – serotonin–norepinephrine–dopamine releasing agent, serotonin 5-HT_2A, 5-HT_2B, and 5-HT_2C receptor agonist, and psychedelic hallucinogen – "ataractic, psychic energizer, analgetic" –

Smith, Kline & French Smith, Kline & French (SKF) was an American pharmaceutical company that is now a part of the British group GSK plc. History In 1830, John K. Smith opened a drugstore in Philadelphia, and his younger brother, George, joined him in 1841 to form ...

* (''R'')-Ariadne (BL-3912A; Dimoxamine) – non-hallucinogenic serotonin 5-HT_2A, 5-HT_2B, and 5-HT_2C receptor agonist – depression – Bristol-Myers Company * Diethyltryptamine (DET; T-9) – non-selective serotonin receptor agonist and psychedelic hallucinogen – unknown – unknown *

2,5-Dimethoxy-4-bromoamphetamine Dimethoxybromoamphetamine (DOB), also known as brolamfetamine () and bromo-DMA, is a psychedelic drug and substituted amphetamine of the phenethylamine class of compounds. DOB was first synthesized by Alexander Shulgin in 1967. Its synthesis ...

(DOB; brolamfetamine) – serotonin 5-HT_2A, 5-HT_2B, and 5-HT_2C receptor agonist and psychedelic hallucinogen – unknown – unknown *

2,5-Dimethoxy-4-ethylamphetamine 2,5-Dimethoxy-4-ethylamphetamine (DOET) is a psychedelic drug of the phenethylamine, amphetamine, and DOx families. It is closely related to DOM and is a synthetic analogue of the naturally occurring phenethylamine psychedelic mescaline. ...

(DOET) – serotonin 5-HT_2A, 5-HT_2B, and 5-HT_2C receptor agonist and psychedelic hallucinogen – unknown –

Dow Chemical Company The Dow Chemical Company is an American multinational corporation headquartered in Midland, Michigan, United States. The company was among the three largest chemical producers in the world in 2021. It is the operating subsidiary of Dow Inc., ...

2,5-Dimethoxy-4-methylamphetamine 2,5-Dimethoxy-4-methylamphetamine (DOM), also known as STP (standing for "Serenity, Tranquility, and Peace" and/or other phrases), is a psychedelic drug of the phenethylamine, amphetamine, and DOx families. It is generally taken orally. DOM w ...

(DOM; K-61,082) – serotonin 5-HT_2A, 5-HT_2B, and 5-HT_2C receptor agonist and psychedelic hallucinogen – unknown – Dow Chemical Company * Ethocybin (4-PO-DET; CEY-19) – non-selective serotonin receptor agonist and psychedelic hallucinogen – unknown – Sandoz * 4-Hydroxy-''N'',''N''-diethyltryptamine (4-HO-DET; CZ-74) – non-selective serotonin receptor agonist and psychedelic hallucinogen – unknown – Sandoz * 4-Hydroxy-α-methyltryptamine (4-HO-AMT; MP-14) – undefined mechanism of action – unknown – unknown *

(LSD; LSD-25; lysergide; Delysid) – non-selective serotonin receptor agonist and psychedelic hallucinogen – various uses –

Sandoz Sandoz Group AG is a Swiss company that focuses on generic pharmaceuticals and biosimilars. Prior to October 2023, it was part of a division of Novartis that was established in 2003, when Novartis united all of its generics businesses under the ...

(mezcalin) – serotonin 5-HT_2A, 5-HT_2B, and 5-HT_2C receptor agonist and psychedelic hallucinogen – various uses – Merck * 4-Methyl-α-methyltryptamine (4-Me-AMT; MP-809) – undefined mechanism of action – depression – Sandoz * 3,4-Methylenedioxyamphetamine (MDA; SKF-5; Amphedoxamine) – serotonin, norepinephrine, and dopamine releasing agent, weak serotonin 5-HT_2A, 5-HT_2B, and 5-HT_2C receptor agonist, entactogen, and weak psychedelic hallucinogen – appetite suppressant – Smith, Kline, & French * 3,4-Methylenedioxyamphetamine (MDA; tenamfetamine) – serotonin, norepinephrine, and dopamine releasing agent, weak serotonin 5-HT_2A, 5-HT_2B, and 5-HT_2C receptor agonist, entactogen, and weak psychedelic hallucinogen – unknown – unknown *

(4-HO-DMT; CX-59) – non-selective serotonin receptor agonist and psychedelic hallucinogen – various uses – Sandoz *

(4-PO-DMT; CY-39; Indocybin) – non-selective serotonin receptor agonist and psychedelic hallucinogen – various uses – Sandoz

Formal development never or not yet started

Nitrous oxide Nitrous oxide (dinitrogen oxide or dinitrogen monoxide), commonly known as laughing gas, nitrous, or factitious air, among others, is a chemical compound, an Nitrogen oxide, oxide of nitrogen with the Chemical formula, formula . At room te ...

(N₂O; "laughing gas") – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – being studied for depression but doesn't seem to be being formally developed towards approval

Other related drugs

1Z2MAP1O 1Z2MAP1O, also known as 1-(indolizin-3-yl)-2-(methylamino)propan-1-one, is a monoamine releasing agent and serotonin receptor receptor modulator, modulator of the indolizine class. It is an structural analog, analogue of BK-NM-AMT (β-keto-''N''- ...

* 1ZP2MA * 5-Chloro-αMT (PAL-542) * 5-Fluoro-AMT (5F-AMT; PAL-212, PAL-544) *

5-MAPB 5-MAPB, also known as 5-(''N''-methyl-2-aminopropyl)benzofuran, is an entactogen and designer drug of the amphetamine family that is similar to MDMA in its structure and effects. It has been patented by Tactogen as an entactogen for potential ...

* 5-MAPBT * 5-MBPB (5-MPBP, 5-MABB) * 6-MBPB (6-MPBP, 6-MABB) * BFAI * BK-5-MAPB * BK-5Br-NM-AMT * BK-5Cl-NM-AMT * BK-5F-NM-AMT * BK-NM-AMT *

CYB210010 CYB210010, also known as 2C-T-TFM or 2C-T-36 and as 2,5-dimethoxy-4-(trifluoromethylsulfanyl)phenethylamine, is a lesser-known psychedelic drug of the phenethylamine family related to compounds such as 2C-T and 2C-T-21. Alexander Shulgin atte ...

(2C-T-TFM; 2C-T-36) * DLX-2270 * Gaboxadol (THIP; LU-02030, MK-0928, OV-101) * HBL20016 * Ibogainalog (IBG) * Ibogaminalog (DM-506) * IHCH-7079 * IHCH-7086 * IHCH-7113 * Noribogainalog * JRT *

Lisuride Lisuride, sold under the brand name Dopergin among others, is a monoaminergic medication of the ergoline family which is used in the treatment of Parkinson's disease, migraine, and high prolactin levels. It is taken by mouth. Side effects of l ...

ODMA The Open Document Management API is an API that simplifies the communication of desktop applications with document management systems (DMS). ODMA standardizes the access to the DMS, which makes getting to these files as easy as if the files wer ...

* ORG-12962 * ORG-37684 * Oxa-noribogaine * RE-109 (''O''-glutarylpsilocin; 4-GO-DMT) * SeDMA * TDMA

Clinically used drugs

Approved drugs

* Bupropion/dextromethorphan (DXM/BUP; Auvelity) – sigma σ₁ receptor agonist, serotonin reuptake inhibitor, norepinephrine and dopamine reuptake inhibitor, nicotinic acetylcholine receptor negative allosteric modulator, ionotropic glutamate NMDA receptor antagonist, other actions, CYP2D6 inhibitor, and dissociative hallucinogen combination – major depressive disorder – Axsome Therapeutics *

((''S'')-ketamine; Spravato) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – major depressive disorder – Johnson & Johnson

Off-label drugs

– ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – major depressive disorder, other depressive disorders, and other conditions

Discontinued drugs

* α-Methyltryptamine (Indopan; αMT; AMT) – serotonin–norepinephrine–dopamine releasing agent, non-selective serotonin receptor agonist, weak monoamine oxidase inhibitor, entactogen, and psychedelic hallucinogen – depression – unknown (marketed in the Soviet Union) * Etryptamine (Monase; α-ethyltryptamine; αET; AET) – serotonin–norepinephrine–dopamine releasing agent, serotonin receptor agonist, weak monoamine oxidase inhibitor, and entactogen – depression – Upjohn * '' Tabernanthe spp.''

extract An extract (essence) is a substance made by extracting a part of a raw material, often by using a solvent such as ethanol, oil or water. Extracts may be sold as tinctures or absolutes or dried and powdered. The aromatic principles of ma ...

s (containing

ibogaine Ibogaine is a psychoactive indole alkaloid derived from plants such as '' Tabernanthe iboga'', characterized by hallucinogenic and oneirogenic effects. Traditionally used by Central African foragers, it has undergone controversial research ...

) (Lambarène, Iperton) – various actions and stimulant – fatigue, asthenia, depression, illness recovery

References

External links

AdisInsight - Springer

Psychedelics Drug Development Tracker - Psychedelic Alpha

Psychedelic Drug Development Tracker Bullseye (Q1 2025) - Psychedelic Alpha
{{DEFAULTSORT:Investigational hallucinogens Drug-related lists Dynamic lists Experimental entactogens Experimental hallucinogens Psychedelic drug research Psychedelic pharmaceutical companies